Amodiaquine
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Amodiaquine: 4-aminoquinoline antimalarial → pulmonary hypertension
One-Sentence Summary
Amodiaquine is an oral antimalarial of the 4-aminoquinoline class, currently marketed in India. The TxGNN model predicts it may be effective for pulmonary hypertension, but this is a model prediction only: no clinical trials and no publications were found to support it, so it should be treated as a hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | pulmonary hypertension |
| TxGNN Prediction Score | 0.9925 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general knowledge, amodiaquine belongs to the 4-aminoquinoline class of antimalarials. The data compiled for this report contain no mechanistic rationale connecting the drug to pulmonary hypertension.
The relationship between the drug’s existing use and pulmonary hypertension cannot be assessed from the available data. The prediction rests solely on the model’s score. A high score alone does not show that the drug acts on the pathways involved in pulmonary vascular disease, and no study has tested this. Any mechanistic link would have to be established through further research.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 79388 | Eriquin 200mg Tablet | strip of 10 tablets | Not recorded |
| 28083 | Basoquin Suspension | bottle of 30 ml Suspension | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for pulmonary hypertension has a high model score but no supporting clinical trials or publications, and no mechanistic rationale is available. Evidence is at the model-prediction-only level (L5).
To proceed, the following is needed:
- Mechanism of action data to assess biological plausibility for pulmonary hypertension
- Preclinical or early clinical studies that directly address pulmonary hypertension
- Package insert warnings and contraindications from the Indian licence holders, for safety screening
- Assessment of route and dosage-form compatibility with the needs of the new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.